ASCO 2026: Breakthroughs Elicit Rare Standing Ovations-Key Takeaways from Day 3
At this week’s American Society of Clinical Oncology (ASCO) annual meeting, two biotech firms—RevMed and Akeso—took center stage, but with wildly divergent outcomes. RevMed’s RVM-101, a first-in-class PD-1/PD-L1 bispecific antibody ... Read More